For research use only. Not for therapeutic Use.
URB447 is a mixed central cannabinoid (CB<sub>1</sub>) receptor antagonist/peripheral cannabinoid (CB<sub>2</sub>) receptor agonist with IC<sub>50</sub> values of 313 and 41 nM, respectively. At 20 mg/kg delivered intraperitoneally to <em>ob/ob</em> mice and Swiss mice, URB447 reduces food intake and body-<wbr></wbr>weight gain with an efficacy comparable to rimonabant, which is an inverse agonist for the CB<sub>1</sub>. Marketed as an anti-<wbr></wbr>obesity drug and appetite suppressant, rimonabant was subsequently suspended from distribution due to serious psychiatric side effects attributed to its indiscriminate activity on CB<sub>1</sub> receptors in the central nervous system (CNS). Unlike rimonabant, URB447 does not penetrate the blood-<wbr></wbr>brain barrier (to antagonize CB<sub>1</sub> receptors in the CNS); instead, it appears to selectively block peripheral CB<sub>1</sub> receptors such as those located in the gastrointestinal tract.
| Catalog Number | R036533 |
| CAS Number | 1132922-57-6 |
| Synonyms | [4-Amino-1-[(4-chlorophenyl)methyl]-2-methyl-5-phenyl-1H-pyrrol-3-yl]phenylmethanone |
| Molecular Formula | C25H21ClN2O |
| Purity | ≥95% |
| Target | Neuronal Signaling |
| Storage | -20°C |
| IUPAC Name | [4-amino-1-[(4-chlorophenyl)methyl]-2-methyl-5-phenylpyrrol-3-yl]-phenylmethanone |
| InChI | InChI=1S/C25H21ClN2O/c1-17-22(25(29)20-10-6-3-7-11-20)23(27)24(19-8-4-2-5-9-19)28(17)16-18-12-14-21(26)15-13-18/h2-15H,16,27H2,1H3 |
| InChIKey | KGXYGMKEFDUWNB-UHFFFAOYSA-N |
| SMILES | CC1=C(C(=C(N1CC2=CC=C(C=C2)Cl)C3=CC=CC=C3)N)C(=O)C4=CC=CC=C4 |
